"Starpharma is now in a particularly strong position to expedite and expand the development of internal DEP® candidates and broaden our pipeline to run more DEP® clinical trials in parallel, while continuing to commercialise the VivaGel® portfolio.” “The remainder of 2017 represents a particularly exciting period for Starpharma"
The CEO is really starting to talk like a full blown Pharma rather than a little Biotech, Yes we have an oncology pipeline pretty damn exciting imo.
The Pipeline
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
